Trial Profile
A Randomized, International, Multi-center, Open-label Study to Document Pharmacokinetics and Optimal Timing of Initiation of Dronedarone Treatment Following Long-term Amiodarone in Patients With Paroxysmal or Persistent Atrial Fibrillation Whatever the Reason for the Change of Treatment.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Oct 2021
Price :
$35
*
At a glance
- Drugs Dronedarone (Primary)
- Indications Atrial fibrillation
- Focus Pharmacogenomic; Pharmacokinetics
- Acronyms ARTEMIS AF Long-Term
- Sponsors Sanofi
- 08 Dec 2020 The Greece was the planned location as per European Clinical Trials Database record.
- 20 Apr 2012 Actual patient number is 156 according to ClinicalTrials.gov.
- 20 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.